908 Devices Inc.MASSEarnings & Financial Report
908 Devices Inc. develops and manufactures portable, high-performance mass spectrometry devices and analytical solutions. Its products serve use cases across life science research, biopharmaceutical manufacturing, public safety, forensics, and industrial process monitoring, catering to global customers including research institutions, pharmaceutical firms and government agencies.
Revenue
$13.0M
Gross Profit
$6.4M
Operating Profit
$-15.2M
Net Profit
$-13.3M
Gross Margin
48.9%
Operating Margin
-116.3%
Net Margin
-102.1%
YoY Growth
13.7%
EPS
$-0.37
908 Devices Inc. Q2 FY2025 Financial Summary
908 Devices Inc. reported revenue of $13.0M (up 13.7% YoY) for Q2 FY2025, with a net profit of $-13.3M (down 6.0% YoY) (-102.1% margin). Cost of goods sold was $6.7M, operating expenses totaled $21.5M.
Key Financial Metrics
| Total Revenue | $13.0M |
|---|---|
| Net Profit | $-13.3M |
| Gross Margin | 48.9% |
| Operating Margin | -116.3% |
| Report Period | Q2 FY2025 |
908 Devices Inc. Annual Revenue by Year
908 Devices Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $56.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $56.2M |
| 2024 | $47.7M |
| 2023 | $50.2M |
| 2022 | $46.9M |
908 Devices Inc. Quarterly Revenue & Net Profit History
908 Devices Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $17.4M | +21.2% | $4.2M | 24.0% |
| Q3 FY2025 | $14.0M | -3.5% | $-15.0M | -107.0% |
| Q2 FY2025 | $13.0M | +13.7% | $-13.3M | -102.1% |
| Q1 FY2025 | $11.8M | +58.7% | $43.6M | 370.2% |
| Q4 FY2024 | $14.3M | -0.1% | $-19.4M | -135.6% |
| Q3 FY2024 | $14.5M | +1.6% | $-29.3M | -201.8% |
| Q2 FY2024 | $11.5M | -5.2% | $-12.5M | -109.5% |
| Q1 FY2024 | $7.4M | -21.8% | $-10.9M | -147.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $11.5M | $14.5M | $14.3M | $11.8M | $13.0M | $14.0M | $17.4M |
| YoY Growth | -21.8% | -5.2% | 1.6% | -0.1% | 58.7% | 13.7% | -3.5% | 21.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $189.8M | $208.8M | $178.3M | $159.5M | $196.0M | $191.7M | $190.9M | $190.1M |
| Liabilities | $32.9M | $52.4M | $47.2M | $44.9M | $36.6M | $42.9M | $54.6M | $46.4M |
| Equity | $156.9M | $156.4M | $131.0M | $114.6M | $159.4M | $148.8M | $136.3M | $143.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.4M | $-13.0M | $-5.6M | $-2.2M | $-15.0M | $-5.8M | $-4.2M | $1.3M |